Fed. Circ. Affirms Bristol-Myers, Pfizer Win In Eliquis IP Row

By Britain Eakin (September 3, 2021, 7:53 PM EDT) -- The Federal Circuit on Friday affirmed that two patents on Bristol-Myers Squibb and Pfizer's blockbuster blood clot treatment Eliquis are valid and infringed by generic manufacturers, with the pharmaceutical companies saying the ruling will shut generic versions out until 2028....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!